Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat

Imported from official source

Alert

Safety Classified by Officially

There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and associated evidence, the MHRA has proposed updates to the product information. Interim monitoring advice is being provided by the MHRA based on these proposals, pending independent review and finalisation of the MHRA’s position.

  • continue to refrain from using Duvyzat® in patients at increased risk for ventricular arrhythmias, such as those with congenital long QT syndrome, coronary artery disease, electrolyte disturbances, or those taking other medicines known to cause QT prolongation
  • continue to follow the Duchenne Care UK (North Star) clinical guidance, which provides information on cardiac monitoring and clinical monitoring
  • obtain ECGs before initiating treatment, within 2-4 weeks after starting givinostat, and then every 6 months thereafter, in line with Duchenne Care UK (North Star) clinical guidance. The guidance also provides advice on thresholds for cardiology input. Additionally, the MHRA advises that 24-hour ambulatory ECG monitoring should also be undertaken at baseline, and repeated when the patient is on a stable dose of medication
  • the MHRA also advises that serum electrolytes (including potassium, magnesium and calcium) should be monitored at the same frequency as haematological bloods every 2 weeks for the first 2 months of treatment, at month 3, and then every 3 months thereafter
  • Duvyzat®▼ (givinostat) is a black triangle medicine and is subject to additional monitoring. Report ALL suspected adverse drug reactions associated with Duvyzat® on a Yellow Card
  • Advice for Healthcare Professionals to Provide to Patients:

    This is an extract. The publication continues at the source.

    Contains public sector information licensed under the Open Government Licence v3.0. Licence

    Read the original at the source: https://www.gov.uk/drug-safety-update/duvyzat-r-v-givinostat-interim-advice-on-risk-mitigation-measures-following-reports-of-deaths-in-patients-while-taking-givinostat

    Officially imported this from Medicines and Healthcare products Regulatory Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

    Provenance

    Organization
    Medicines and Healthcare products Regulatory Agency — imported from official source
    Official source
    https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency.atom ATOM
    Imported
    November 05, 2026 13:02
    Versions
    1 recorded
    Identity
    https://www.gov.uk/drug-safety-update/duvyzat-r-v-givinostat-interim-advice-on-risk-mit...

    Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.